Health Care • Biotechnology: Pharmaceutical Preparations
$37.23 ▼ -0.89
(-2.33%)
MKT CAP: $2.22B • VOL: 984.5K
52W L $22 52W H $46
AGIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $54.0M | $36.5M | $26.8M |
| YoY Revenue Growth % | +48.0% | +36.1% | — |
| Gross Profit | $47.7M | $32.3M | — |
| Gross Margin % | 88.3% | 88.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$472.1M | -$425.7M | -$391.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$413.0M | $674.0M | -$352.0M |
| EBITDA (Normalized) | -$468.7M | -$424.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$373.0M | -$389.8M | -$296.1M |
| Capital Expenditures (CapEx) | $4.3M | $1.7M | — |
| Free Cash Flow (FCF) | -$377.3M | -$391.5M | -$296.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -33.8% | -23.0% | — |
| Cash & Short-Term Equivalents | $89.1M | $76.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.19B | $1.54B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AGIO.